 Xianzhong Meng
Concepts (401)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aortic Valve | 40 | 2023 | 355 | 12.100 |
Why?
| | Aortic Valve Stenosis | 30 | 2023 | 256 | 8.840 |
Why?
| | Toll-Like Receptor 4 | 32 | 2021 | 293 | 6.490 |
Why?
| | Calcinosis | 22 | 2022 | 256 | 6.480 |
Why?
| | Osteogenesis | 17 | 2022 | 193 | 5.070 |
Why?
| | Toll-Like Receptor 2 | 12 | 2022 | 115 | 3.680 |
Why?
| | NF-kappa B | 25 | 2022 | 639 | 3.230 |
Why?
| | Intercellular Adhesion Molecule-1 | 17 | 2022 | 152 | 2.840 |
Why?
| | Bone Morphogenetic Protein 2 | 14 | 2018 | 77 | 2.580 |
Why?
| | Cells, Cultured | 37 | 2023 | 3956 | 2.290 |
Why?
| | Myocardium | 12 | 2017 | 944 | 2.060 |
Why?
| | Monocytes | 3 | 2022 | 507 | 1.940 |
Why?
| | Heart Valve Diseases | 5 | 2020 | 122 | 1.900 |
Why?
| | Glucuronidase | 3 | 2020 | 44 | 1.880 |
Why?
| | Interleukin-1 | 6 | 2023 | 973 | 1.820 |
Why?
| | Endotoxemia | 7 | 2017 | 85 | 1.750 |
Why?
| | Myocardial Reperfusion Injury | 5 | 2015 | 95 | 1.600 |
Why?
| | Lipoproteins, LDL | 5 | 2017 | 131 | 1.590 |
Why?
| | Biglycan | 4 | 2017 | 8 | 1.570 |
Why?
| | Up-Regulation | 14 | 2020 | 837 | 1.550 |
Why?
| | Signal Transduction | 30 | 2023 | 4606 | 1.450 |
Why?
| | Reperfusion Injury | 8 | 2022 | 256 | 1.360 |
Why?
| | Interleukins | 4 | 2022 | 238 | 1.330 |
Why?
| | Receptor, Notch1 | 3 | 2014 | 61 | 1.320 |
Why?
| | Neurotrophin 3 | 2 | 2020 | 13 | 1.300 |
Why?
| | Matrilin Proteins | 4 | 2022 | 10 | 1.300 |
Why?
| | Proto-Oncogene Proteins c-akt | 5 | 2020 | 406 | 1.290 |
Why?
| | Myofibroblasts | 4 | 2018 | 114 | 1.230 |
Why?
| | Inflammation Mediators | 4 | 2022 | 486 | 1.200 |
Why?
| | Lipopolysaccharides | 17 | 2020 | 825 | 1.170 |
Why?
| | Tumor Necrosis Factor-alpha | 9 | 2013 | 1136 | 1.150 |
Why?
| | Heart | 8 | 2017 | 623 | 1.150 |
Why?
| | Transforming Growth Factor beta1 | 3 | 2017 | 159 | 1.120 |
Why?
| | Down-Regulation | 6 | 2020 | 606 | 1.030 |
Why?
| | Matrix Metalloproteinases | 2 | 2017 | 89 | 1.030 |
Why?
| | Coronary Vessels | 2 | 2021 | 227 | 1.030 |
Why?
| | Vascular Calcification | 2 | 2017 | 117 | 1.010 |
Why?
| | Esophageal Neoplasms | 10 | 2022 | 276 | 0.990 |
Why?
| | Collagen | 4 | 2022 | 423 | 0.990 |
Why?
| | Chemokine CCL2 | 5 | 2017 | 121 | 0.980 |
Why?
| | Recombinant Proteins | 10 | 2023 | 1258 | 0.960 |
Why?
| | Inflammation | 10 | 2021 | 2515 | 0.940 |
Why?
| | Spinal Cord Ischemia | 8 | 2018 | 63 | 0.930 |
Why?
| | MicroRNAs | 3 | 2019 | 627 | 0.910 |
Why?
| | Endothelial Cells | 3 | 2021 | 698 | 0.890 |
Why?
| | Extracellular Matrix Proteins | 3 | 2021 | 130 | 0.830 |
Why?
| | Chemokines | 4 | 2015 | 219 | 0.810 |
Why?
| | Heart Diseases | 2 | 2022 | 336 | 0.800 |
Why?
| | Anti-Inflammatory Agents | 3 | 2023 | 456 | 0.790 |
Why?
| | Group II Phospholipases A2 | 7 | 2020 | 16 | 0.780 |
Why?
| | Adenocarcinoma | 10 | 2022 | 793 | 0.770 |
Why?
| | Receptor, trkA | 2 | 2020 | 18 | 0.760 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 4 | 2020 | 168 | 0.760 |
Why?
| | HSP70 Heat-Shock Proteins | 4 | 2017 | 72 | 0.760 |
Why?
| | Mice, Inbred C57BL | 22 | 2022 | 4839 | 0.740 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 4 | 2021 | 150 | 0.740 |
Why?
| | Disease Susceptibility | 1 | 2022 | 327 | 0.700 |
Why?
| | Osteoblasts | 2 | 2017 | 112 | 0.690 |
Why?
| | Phospholipases A2, Secretory | 6 | 2019 | 22 | 0.680 |
Why?
| | Animals | 47 | 2023 | 32736 | 0.680 |
Why?
| | Aging | 3 | 2022 | 1653 | 0.670 |
Why?
| | Alkaline Phosphatase | 7 | 2019 | 152 | 0.670 |
Why?
| | HSC70 Heat-Shock Proteins | 2 | 2009 | 4 | 0.660 |
Why?
| | Mice | 36 | 2023 | 15308 | 0.660 |
Why?
| | Toll-Like Receptor 3 | 2 | 2017 | 29 | 0.650 |
Why?
| | Male | 50 | 2022 | 56660 | 0.650 |
Why?
| | Gastroesophageal Reflux | 6 | 2022 | 239 | 0.650 |
Why?
| | Myeloid Differentiation Factor 88 | 3 | 2020 | 91 | 0.650 |
Why?
| | Myocardial Contraction | 3 | 2008 | 328 | 0.620 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2022 | 381 | 0.620 |
Why?
| | Humans | 68 | 2023 | 117047 | 0.610 |
Why?
| | Middle Aged | 25 | 2022 | 27170 | 0.610 |
Why?
| | Barrett Esophagus | 5 | 2022 | 151 | 0.600 |
Why?
| | ADAMTS5 Protein | 1 | 2017 | 6 | 0.600 |
Why?
| | Heart Defects, Congenital | 3 | 2020 | 686 | 0.600 |
Why?
| | Neutrophil Infiltration | 3 | 2009 | 91 | 0.590 |
Why?
| | Cell Transdifferentiation | 1 | 2017 | 31 | 0.580 |
Why?
| | SOX9 Transcription Factor | 1 | 2017 | 23 | 0.580 |
Why?
| | Lysophosphatidylcholines | 1 | 2017 | 20 | 0.580 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 7 | 2023 | 45 | 0.580 |
Why?
| | Cyclin D1 | 1 | 2017 | 60 | 0.580 |
Why?
| | HSP27 Heat-Shock Proteins | 2 | 2014 | 11 | 0.580 |
Why?
| | RNA, Double-Stranded | 1 | 2017 | 45 | 0.570 |
Why?
| | Cell Proliferation | 11 | 2020 | 2236 | 0.560 |
Why?
| | Phosphates | 1 | 2017 | 163 | 0.540 |
Why?
| | Epigenesis, Genetic | 2 | 2017 | 546 | 0.540 |
Why?
| | RNA Interference | 6 | 2017 | 452 | 0.530 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 4 | 2022 | 37 | 0.520 |
Why?
| | Immunity, Innate | 3 | 2019 | 742 | 0.520 |
Why?
| | Aged | 16 | 2019 | 19356 | 0.520 |
Why?
| | Extracellular Space | 3 | 2010 | 123 | 0.510 |
Why?
| | Enzyme Inhibitors | 6 | 2020 | 775 | 0.470 |
Why?
| | Ventricular Function, Left | 1 | 2017 | 470 | 0.460 |
Why?
| | Immune Tolerance | 2 | 2019 | 329 | 0.450 |
Why?
| | Myocarditis | 3 | 2011 | 94 | 0.450 |
Why?
| | Simvastatin | 5 | 2022 | 61 | 0.450 |
Why?
| | Receptors, Erythropoietin | 3 | 2018 | 21 | 0.440 |
Why?
| | Myocardial Ischemia | 3 | 2011 | 242 | 0.430 |
Why?
| | Mice, Knockout | 9 | 2017 | 2648 | 0.410 |
Why?
| | Interleukin-6 | 5 | 2022 | 673 | 0.400 |
Why?
| | Erythropoietin | 3 | 2018 | 75 | 0.390 |
Why?
| | Esophagus | 4 | 2020 | 230 | 0.390 |
Why?
| | Spinal Cord | 5 | 2018 | 353 | 0.380 |
Why?
| | Cytokines | 7 | 2017 | 1852 | 0.370 |
Why?
| | Matrix Metalloproteinase 9 | 2 | 2022 | 122 | 0.370 |
Why?
| | Mice, Inbred C3H | 6 | 2021 | 240 | 0.360 |
Why?
| | Interleukin-1beta | 2 | 2013 | 368 | 0.360 |
Why?
| | Transfection | 5 | 2017 | 877 | 0.360 |
Why?
| | Shock, Hemorrhagic | 3 | 2012 | 147 | 0.350 |
Why?
| | Gene Knockdown Techniques | 3 | 2017 | 310 | 0.350 |
Why?
| | Case-Control Studies | 5 | 2017 | 3099 | 0.350 |
Why?
| | Lipopeptides | 2 | 2020 | 14 | 0.340 |
Why?
| | Lung Neoplasms | 7 | 2019 | 2221 | 0.340 |
Why?
| | Endotoxins | 1 | 2010 | 208 | 0.340 |
Why?
| | Female | 16 | 2022 | 60630 | 0.320 |
Why?
| | Actins | 3 | 2017 | 386 | 0.320 |
Why?
| | Actin Cytoskeleton | 1 | 2009 | 99 | 0.320 |
Why?
| | Calcium-Binding Proteins | 3 | 2015 | 211 | 0.310 |
Why?
| | Receptors, Cell Surface | 3 | 2004 | 355 | 0.300 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2008 | 366 | 0.300 |
Why?
| | Esophagitis, Peptic | 2 | 2022 | 16 | 0.290 |
Why?
| | Disease Models, Animal | 13 | 2022 | 3648 | 0.290 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 5 | 2018 | 258 | 0.280 |
Why?
| | Phenotype | 7 | 2017 | 2891 | 0.280 |
Why?
| | RNA, Small Interfering | 3 | 2014 | 561 | 0.260 |
Why?
| | Immunoblotting | 3 | 2017 | 292 | 0.260 |
Why?
| | Dexmedetomidine | 3 | 2014 | 46 | 0.250 |
Why?
| | Interleukin-18 | 2 | 2006 | 224 | 0.250 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 4 | 2014 | 974 | 0.250 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2004 | 76 | 0.240 |
Why?
| | Ischemia | 2 | 2022 | 368 | 0.240 |
Why?
| | Intercellular Signaling Peptides and Proteins | 3 | 2013 | 350 | 0.230 |
Why?
| | Neuroprotective Agents | 2 | 2018 | 106 | 0.230 |
Why?
| | Biomarkers | 4 | 2022 | 3549 | 0.230 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2017 | 798 | 0.230 |
Why?
| | Gene Expression Regulation | 6 | 2017 | 2408 | 0.230 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 2 | 2014 | 25 | 0.230 |
Why?
| | Spinal Cord Injuries | 2 | 2018 | 175 | 0.220 |
Why?
| | Apoptosis | 5 | 2018 | 2433 | 0.220 |
Why?
| | Jagged-1 Protein | 2 | 2013 | 23 | 0.220 |
Why?
| | Serrate-Jagged Proteins | 2 | 2013 | 28 | 0.220 |
Why?
| | Fluorescent Antibody Technique | 7 | 2010 | 400 | 0.220 |
Why?
| | Phosphorylation | 5 | 2013 | 1590 | 0.220 |
Why?
| | MAP Kinase Signaling System | 2 | 2015 | 274 | 0.220 |
Why?
| | Mice, Transgenic | 3 | 2017 | 1993 | 0.220 |
Why?
| | Receptors, Interleukin-9 | 1 | 2022 | 3 | 0.220 |
Why?
| | Smad1 Protein | 2 | 2014 | 18 | 0.210 |
Why?
| | CD18 Antigens | 1 | 2022 | 26 | 0.210 |
Why?
| | Infarction | 1 | 2022 | 13 | 0.210 |
Why?
| | Neoplasm Proteins | 2 | 2019 | 396 | 0.200 |
Why?
| | Culture Media, Conditioned | 1 | 2022 | 106 | 0.200 |
Why?
| | Heat-Shock Proteins | 2 | 2014 | 121 | 0.200 |
Why?
| | Tumor Burden | 2 | 2020 | 270 | 0.200 |
Why?
| | Diazoxide | 2 | 2018 | 22 | 0.200 |
Why?
| | Lab-On-A-Chip Devices | 1 | 2021 | 36 | 0.200 |
Why?
| | Microglia | 2 | 2013 | 207 | 0.200 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 7 | 2015 | 965 | 0.190 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2022 | 147 | 0.190 |
Why?
| | Caspases | 1 | 2022 | 259 | 0.190 |
Why?
| | Pentanoic Acids | 1 | 2020 | 2 | 0.190 |
Why?
| | Time Factors | 7 | 2014 | 6240 | 0.190 |
Why?
| | Inflammasomes | 1 | 2022 | 118 | 0.190 |
Why?
| | In Vitro Techniques | 3 | 2009 | 1049 | 0.190 |
Why?
| | Mice, Inbred NOD | 1 | 2022 | 567 | 0.190 |
Why?
| | Adaptor Proteins, Vesicular Transport | 2 | 2019 | 45 | 0.180 |
Why?
| | Gene Expression | 4 | 2009 | 1466 | 0.180 |
Why?
| | Dinoprostone | 2 | 2019 | 191 | 0.180 |
Why?
| | Indole Alkaloids | 1 | 2020 | 10 | 0.180 |
Why?
| | eIF-2 Kinase | 1 | 2020 | 25 | 0.180 |
Why?
| | Primary Cell Culture | 2 | 2018 | 148 | 0.180 |
Why?
| | Carbazoles | 1 | 2020 | 79 | 0.170 |
Why?
| | STAT3 Transcription Factor | 3 | 2019 | 180 | 0.170 |
Why?
| | Cell Line, Tumor | 9 | 2020 | 2813 | 0.170 |
Why?
| | Blotting, Western | 7 | 2020 | 1172 | 0.170 |
Why?
| | Wnt Signaling Pathway | 1 | 2020 | 149 | 0.170 |
Why?
| | Matrix Metalloproteinase 12 | 1 | 2018 | 7 | 0.160 |
Why?
| | Cell Movement | 2 | 2014 | 877 | 0.160 |
Why?
| | Cell Adhesion Molecules | 2 | 2021 | 171 | 0.160 |
Why?
| | RNA, Neoplasm | 1 | 2018 | 76 | 0.160 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2020 | 1158 | 0.160 |
Why?
| | Heme Oxygenase-1 | 2 | 2009 | 48 | 0.160 |
Why?
| | Cell Line | 3 | 2020 | 2670 | 0.150 |
Why?
| | Neutrophils | 6 | 2012 | 1081 | 0.150 |
Why?
| | Sp7 Transcription Factor | 1 | 2017 | 7 | 0.150 |
Why?
| | Antagomirs | 1 | 2017 | 13 | 0.150 |
Why?
| | Sclerosis | 1 | 2017 | 12 | 0.150 |
Why?
| | Toll-Like Receptors | 2 | 2017 | 166 | 0.150 |
Why?
| | Mice, Mutant Strains | 2 | 2008 | 273 | 0.150 |
Why?
| | Collagen Type III | 1 | 2017 | 19 | 0.150 |
Why?
| | Calcium | 2 | 2022 | 1125 | 0.150 |
Why?
| | Poly I-C | 1 | 2017 | 54 | 0.150 |
Why?
| | Mice, Inbred Strains | 3 | 2008 | 404 | 0.140 |
Why?
| | NFATC Transcription Factors | 1 | 2017 | 80 | 0.140 |
Why?
| | Membrane Proteins | 2 | 2013 | 1040 | 0.140 |
Why?
| | Collagen Type I | 1 | 2017 | 113 | 0.140 |
Why?
| | Cattle | 2 | 2010 | 957 | 0.140 |
Why?
| | Adult | 10 | 2018 | 31003 | 0.140 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2017 | 145 | 0.130 |
Why?
| | Biomarkers, Tumor | 2 | 2020 | 1053 | 0.130 |
Why?
| | RNA, Messenger | 8 | 2012 | 2632 | 0.130 |
Why?
| | Molecular Chaperones | 2 | 2014 | 161 | 0.130 |
Why?
| | Protein Kinase C | 1 | 2017 | 283 | 0.130 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2020 | 1889 | 0.130 |
Why?
| | Macrophages | 4 | 2011 | 1297 | 0.130 |
Why?
| | Mucous Membrane | 3 | 2010 | 109 | 0.130 |
Why?
| | Smad3 Protein | 1 | 2014 | 45 | 0.120 |
Why?
| | Transcatheter Aortic Valve Replacement | 1 | 2017 | 148 | 0.120 |
Why?
| | Enzyme Activation | 3 | 2013 | 793 | 0.120 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2014 | 34 | 0.120 |
Why?
| | Models, Biological | 1 | 2022 | 1689 | 0.120 |
Why?
| | Paraplegia | 2 | 2011 | 52 | 0.120 |
Why?
| | Solubility | 1 | 2014 | 232 | 0.110 |
Why?
| | Microfilament Proteins | 1 | 2014 | 129 | 0.110 |
Why?
| | Sodium-Phosphate Cotransporter Proteins, Type III | 1 | 2013 | 5 | 0.110 |
Why?
| | Duodenogastric Reflux | 2 | 2010 | 2 | 0.110 |
Why?
| | Protein Binding | 2 | 2010 | 1949 | 0.110 |
Why?
| | Mice, Inbred BALB C | 4 | 2010 | 1183 | 0.110 |
Why?
| | Calcium Phosphates | 1 | 2013 | 25 | 0.110 |
Why?
| | Osteopontin | 2 | 2012 | 37 | 0.110 |
Why?
| | Drug Evaluation, Preclinical | 3 | 2020 | 170 | 0.110 |
Why?
| | Astrocytes | 1 | 2014 | 172 | 0.110 |
Why?
| | Dipeptides | 1 | 2012 | 50 | 0.110 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 2012 | 43 | 0.100 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2012 | 74 | 0.100 |
Why?
| | ras Proteins | 1 | 2012 | 140 | 0.100 |
Why?
| | Deoxycholic Acid | 2 | 2021 | 15 | 0.100 |
Why?
| | Diiodothyronines | 1 | 2011 | 3 | 0.100 |
Why?
| | Lung | 5 | 2012 | 3588 | 0.100 |
Why?
| | Radiation Injuries | 1 | 2012 | 131 | 0.100 |
Why?
| | Propionates | 1 | 2011 | 34 | 0.100 |
Why?
| | Protein Kinase Inhibitors | 1 | 2017 | 803 | 0.100 |
Why?
| | Aorta, Abdominal | 1 | 2011 | 39 | 0.100 |
Why?
| | Antibodies, Neutralizing | 2 | 2012 | 222 | 0.100 |
Why?
| | Antineoplastic Agents | 2 | 2012 | 1941 | 0.100 |
Why?
| | Motor Activity | 2 | 2013 | 644 | 0.100 |
Why?
| | Genetic Therapy | 1 | 2012 | 266 | 0.090 |
Why?
| | Cardiomyopathies | 1 | 2014 | 298 | 0.090 |
Why?
| | Neoplastic Stem Cells | 1 | 2014 | 335 | 0.090 |
Why?
| | Endothelium, Vascular | 1 | 2017 | 860 | 0.090 |
Why?
| | Ischemic Preconditioning, Myocardial | 1 | 2010 | 30 | 0.090 |
Why?
| | Antibodies | 2 | 2002 | 373 | 0.090 |
Why?
| | Heart Function Tests | 1 | 2010 | 59 | 0.090 |
Why?
| | Interleukin-8 | 2 | 2008 | 235 | 0.090 |
Why?
| | A549 Cells | 2 | 2020 | 51 | 0.090 |
Why?
| | Cell Survival | 4 | 2014 | 1030 | 0.090 |
Why?
| | Actinin | 1 | 2009 | 13 | 0.090 |
Why?
| | Acute Lung Injury | 1 | 2012 | 268 | 0.080 |
Why?
| | Proto-Oncogene Proteins | 1 | 2012 | 615 | 0.080 |
Why?
| | Polymerization | 1 | 2009 | 120 | 0.080 |
Why?
| | Phospholipases A2 | 1 | 2008 | 73 | 0.080 |
Why?
| | Mutation | 2 | 2012 | 3420 | 0.080 |
Why?
| | Ventricular Pressure | 1 | 2008 | 39 | 0.080 |
Why?
| | Random Allocation | 3 | 2020 | 339 | 0.080 |
Why?
| | beta Catenin | 2 | 2021 | 223 | 0.080 |
Why?
| | Peptidoglycan | 1 | 2007 | 26 | 0.080 |
Why?
| | Myocardial Depressant Factor | 1 | 2007 | 2 | 0.080 |
Why?
| | Perfusion | 1 | 2008 | 150 | 0.080 |
Why?
| | Oxyhemoglobins | 1 | 2007 | 21 | 0.080 |
Why?
| | Blood Substitutes | 1 | 2007 | 22 | 0.070 |
Why?
| | Lower Extremity | 1 | 2011 | 338 | 0.070 |
Why?
| | Pulmonary Valve | 1 | 2009 | 90 | 0.070 |
Why?
| | Kupffer Cells | 1 | 2007 | 47 | 0.070 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2012 | 610 | 0.070 |
Why?
| | Hyperplasia | 2 | 2010 | 169 | 0.070 |
Why?
| | Hemoglobins | 1 | 2009 | 315 | 0.070 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2007 | 135 | 0.070 |
Why?
| | Analysis of Variance | 4 | 2012 | 1239 | 0.070 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2008 | 311 | 0.070 |
Why?
| | Caspase 1 | 1 | 2006 | 142 | 0.070 |
Why?
| | Protein Structure, Tertiary | 1 | 2008 | 818 | 0.070 |
Why?
| | Mice, Nude | 2 | 2020 | 653 | 0.060 |
Why?
| | Cell Culture Techniques | 2 | 2019 | 349 | 0.060 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2004 | 33 | 0.060 |
Why?
| | Transforming Growth Factor beta | 1 | 2007 | 456 | 0.060 |
Why?
| | Binding Sites | 1 | 2008 | 1206 | 0.060 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2020 | 730 | 0.060 |
Why?
| | Glutamine | 1 | 2005 | 91 | 0.060 |
Why?
| | Disease Progression | 2 | 2020 | 2467 | 0.060 |
Why?
| | Myocardial Infarction | 1 | 2011 | 960 | 0.060 |
Why?
| | Microscopy, Fluorescence | 2 | 2018 | 404 | 0.060 |
Why?
| | Mycobacterium tuberculosis | 1 | 2006 | 272 | 0.060 |
Why?
| | DNA | 1 | 2010 | 1372 | 0.060 |
Why?
| | Immunohistochemistry | 4 | 2009 | 1657 | 0.060 |
Why?
| | Interferon-gamma | 1 | 2006 | 732 | 0.050 |
Why?
| | Cell Adhesion | 2 | 2020 | 428 | 0.050 |
Why?
| | Vinblastine | 1 | 2002 | 63 | 0.050 |
Why?
| | Leukocyte Elastase | 1 | 2002 | 69 | 0.050 |
Why?
| | Carotid Artery Injuries | 1 | 2002 | 41 | 0.050 |
Why?
| | Tunica Intima | 1 | 2002 | 77 | 0.050 |
Why?
| | Annexin A5 | 1 | 2022 | 23 | 0.050 |
Why?
| | Adenosine Triphosphatases | 1 | 2023 | 157 | 0.050 |
Why?
| | Chemotactic Factors | 1 | 2002 | 48 | 0.050 |
Why?
| | Chemokines, CXC | 1 | 2002 | 59 | 0.050 |
Why?
| | Neoplasm Invasiveness | 2 | 2014 | 453 | 0.050 |
Why?
| | Peroxidase | 3 | 2012 | 149 | 0.050 |
Why?
| | Growth Substances | 1 | 2002 | 133 | 0.050 |
Why?
| | Cell Count | 1 | 2002 | 308 | 0.050 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2019 | 494 | 0.050 |
Why?
| | Flow Cytometry | 3 | 2011 | 1063 | 0.050 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2002 | 180 | 0.050 |
Why?
| | Caspase 3 | 1 | 2022 | 237 | 0.050 |
Why?
| | Receptors, Interleukin-1 | 1 | 2002 | 227 | 0.050 |
Why?
| | Drosophila Proteins | 1 | 2002 | 167 | 0.050 |
Why?
| | Tissue Banks | 1 | 2020 | 18 | 0.050 |
Why?
| | Esophageal Mucosa | 1 | 2020 | 17 | 0.050 |
Why?
| | Warfarin | 1 | 2021 | 136 | 0.050 |
Why?
| | Postoperative Complications | 1 | 2011 | 2198 | 0.050 |
Why?
| | Membrane Glycoproteins | 1 | 2002 | 439 | 0.040 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-6 | 1 | 2018 | 6 | 0.040 |
Why?
| | Tumor Cells, Cultured | 2 | 2011 | 860 | 0.040 |
Why?
| | Fibrosis | 1 | 2020 | 478 | 0.040 |
Why?
| | Protein Multimerization | 1 | 2019 | 160 | 0.040 |
Why?
| | Receptor, ErbB-2 | 1 | 2020 | 303 | 0.040 |
Why?
| | Crystallography, X-Ray | 1 | 2019 | 414 | 0.040 |
Why?
| | Brain | 1 | 2009 | 2381 | 0.040 |
Why?
| | ErbB Receptors | 1 | 2020 | 569 | 0.040 |
Why?
| | Sepsis | 1 | 2002 | 525 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 3 | 2009 | 2321 | 0.030 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2012 | 600 | 0.030 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2018 | 339 | 0.030 |
Why?
| | Tensins | 1 | 2014 | 2 | 0.030 |
Why?
| | Aminosalicylic Acids | 1 | 2014 | 6 | 0.030 |
Why?
| | Glial Cell Line-Derived Neurotrophic Factor | 1 | 2014 | 16 | 0.030 |
Why?
| | Benzenesulfonates | 1 | 2014 | 22 | 0.030 |
Why?
| | Epidermal Growth Factor | 1 | 2014 | 168 | 0.030 |
Why?
| | Sensitivity and Specificity | 2 | 2008 | 1740 | 0.030 |
Why?
| | Foscarnet | 1 | 2013 | 18 | 0.030 |
Why?
| | Nerve Degeneration | 1 | 2013 | 41 | 0.030 |
Why?
| | Minocycline | 1 | 2013 | 26 | 0.030 |
Why?
| | Rats | 3 | 2009 | 5172 | 0.030 |
Why?
| | Cell Growth Processes | 1 | 2012 | 52 | 0.030 |
Why?
| | Leukotriene C4 | 1 | 2012 | 13 | 0.030 |
Why?
| | Leukotriene B4 | 1 | 2012 | 42 | 0.030 |
Why?
| | Monokines | 2 | 2002 | 22 | 0.030 |
Why?
| | Ki-67 Antigen | 1 | 2012 | 105 | 0.030 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2012 | 36 | 0.030 |
Why?
| | Chemokine CXCL2 | 2 | 2002 | 39 | 0.030 |
Why?
| | Heart Transplantation | 1 | 2018 | 661 | 0.030 |
Why?
| | Eicosanoids | 1 | 2012 | 57 | 0.030 |
Why?
| | Pravastatin | 1 | 2011 | 28 | 0.030 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 159 | 0.030 |
Why?
| | Heptanoic Acids | 1 | 2011 | 60 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 232 | 0.020 |
Why?
| | Radiotherapy | 1 | 2012 | 186 | 0.020 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2012 | 280 | 0.020 |
Why?
| | Constriction | 1 | 2011 | 44 | 0.020 |
Why?
| | Culture Media | 1 | 2011 | 157 | 0.020 |
Why?
| | Subclavian Artery | 1 | 2011 | 29 | 0.020 |
Why?
| | Pyrroles | 1 | 2011 | 186 | 0.020 |
Why?
| | Hindlimb | 1 | 2011 | 132 | 0.020 |
Why?
| | Indoles | 1 | 2012 | 311 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2012 | 354 | 0.020 |
Why?
| | Glucose | 1 | 2014 | 931 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2012 | 1206 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2011 | 534 | 0.020 |
Why?
| | Prospective Studies | 1 | 2020 | 6389 | 0.020 |
Why?
| | Hypoxia | 1 | 2014 | 950 | 0.020 |
Why?
| | Organ Specificity | 1 | 2009 | 270 | 0.020 |
Why?
| | Aorta, Thoracic | 1 | 2011 | 244 | 0.020 |
Why?
| | Acute Disease | 1 | 2011 | 916 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2009 | 376 | 0.020 |
Why?
| | Tissue and Organ Harvesting | 1 | 2008 | 68 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2008 | 181 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2008 | 314 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2021 | 9256 | 0.020 |
Why?
| | HSP72 Heat-Shock Proteins | 1 | 2007 | 28 | 0.020 |
Why?
| | Cell Division | 1 | 2009 | 767 | 0.020 |
Why?
| | Probability | 1 | 2008 | 296 | 0.020 |
Why?
| | Age Factors | 1 | 2014 | 2950 | 0.020 |
Why?
| | Prevalence | 1 | 2013 | 2300 | 0.020 |
Why?
| | Precancerous Conditions | 1 | 2008 | 156 | 0.020 |
Why?
| | Quercetin | 1 | 2005 | 11 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2006 | 345 | 0.020 |
Why?
| | Lymphocytes | 1 | 2006 | 340 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2010 | 940 | 0.010 |
Why?
| | Dendritic Cells | 1 | 2006 | 442 | 0.010 |
Why?
| | Group IB Phospholipases A2 | 1 | 2002 | 1 | 0.010 |
Why?
| | Receptors, Phospholipase A2 | 1 | 2002 | 1 | 0.010 |
Why?
| | Oxygen | 1 | 2007 | 828 | 0.010 |
Why?
| | Chelating Agents | 1 | 2002 | 68 | 0.010 |
Why?
| | Binding, Competitive | 1 | 2002 | 201 | 0.010 |
Why?
| | Phospholipases A | 1 | 2002 | 95 | 0.010 |
Why?
| | Chemokine CXCL1 | 1 | 2002 | 65 | 0.010 |
Why?
| | Sialoglycoproteins | 1 | 2002 | 160 | 0.010 |
Why?
| | Cell Separation | 1 | 2002 | 293 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2011 | 1499 | 0.010 |
Why?
| | Infant | 1 | 2014 | 8121 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2002 | 276 | 0.010 |
Why?
| | Carotid Arteries | 1 | 2002 | 184 | 0.010 |
Why?
| | Child, Preschool | 1 | 2014 | 9322 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 2002 | 305 | 0.010 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2002 | 253 | 0.010 |
Why?
| | Trachea | 1 | 2002 | 221 | 0.010 |
Why?
| | Salmonella typhimurium | 1 | 2002 | 159 | 0.010 |
Why?
| | Risk Factors | 1 | 2013 | 8873 | 0.010 |
Why?
| | Pulmonary Alveoli | 1 | 2002 | 373 | 0.010 |
Why?
| | Cell Membrane | 1 | 2002 | 681 | 0.010 |
Why?
| | Escherichia coli | 1 | 2002 | 748 | 0.010 |
Why?
| | Young Adult | 1 | 2013 | 10674 | 0.010 |
Why?
| | Adolescent | 1 | 2014 | 18213 | 0.010 |
Why?
| | Liver | 1 | 2002 | 1744 | 0.010 |
Why?
|
|
Meng's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|